What guidance did Crinetics's management provide for the next earnings period?

What factors drove the changes in Crinetics's revenue and profit?

What is Crinetics's latest dividend and current dividend yield?

What were the key takeaways from Crinetics's earnings call?

What is the market's earnings forecast for Crinetics next quarter?

What is the revenue and EPS growth rate for Crinetics year over year?

What is Crinetics's gross profit margin?

What were the key takeaways from Crinetics’s earnings call?

- **Strong PALSONIFY launch**: 95% of top prescribers contacted, 50% of prescriptions reimbursed early, with Q4 2025 metrics expected. 
- **Financial stability**: $1.1B cash, sufficient runway to 2029, despite Q3 R&D/S&G expenses up 13% and 5%. 
- **Pipeline progress**: Phase 3 trials for Atumelnant (CAH) and paltusotine (carcinoid) starting in Q4 2025; CRN09682 Phase 1/2 trial underway. 
- **Key risks**: Graves' disease and ADPKD programs delayed; no rebate agreements for PALSONIFY. 
- **Growth drivers**: Community prescriber adoption (70% of scripts), Quick Start program, and 12-month payer approvals. 


**【CEO Summary Section】**
- Launched PALSONIFY for acromegaly, with 95% of top prescribers contacted and 50% of prescriptions reimbursed early in the launch. 
- Phase 1 strategy focuses on switching patients from injectables, with 95% of initial prescriptions from switch patients. 
- Positive feedback from community endocrinologists and payers, with prior authorizations approved in days. 
- Q4 2025 will provide first full-quarter metrics, including revenue, new patient starts, and prescriber count. 
- Pipeline updates: Graves' disease candidate delayed due to tox signals; SST3 agonist for ADPKD also delayed. 
- Phase 3 trials for Atumelnant in CAH and paltusotine in carcinoid syndrome progressing, with first patients randomized in Q4 2025. 

**【CFO Financial Commentary】**
- Q3 2025 revenue: $0.1M from Japan licensing deal; no PALSONIFY revenue due to late Q3 approval. 
- R&D expenses: $90.5M (vs. $80.3M prior quarter), driven by clinical trial start-up costs. 
- SG&A expenses: $52.3M (vs. $49.8M prior quarter), reflecting launch investments. 
- Cash position: $1.1B, with guidance for $340-370M net cash use in 2025. 
- Sufficient runway to fund operations into 2029. 

**【Q&A Highlights】**
- **Payer dynamics**: 50% of claims reimbursed, with approvals for up to 12-month supplies. No rebate agreements planned. 
- **Graves' disease candidate**: Delayed IND timelines due to tox signals; backup molecules prioritized. 
- **Atumelnant in CAH**: Cohort 4 data expected in Q1 2026, with focus on glucocorticoid tapering and adrenal androgen suppression. 
- **Commercial strategy**: Focus on community prescribers (70% of prescriptions) and PTC centers (30%), with Quick Start program supporting early access. 
- **Pipeline momentum**: BRAVESST2 Phase 1/2 trial for CRN09682 in SST2-expressing tumors underway, with first patients dosed. 


Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript

Grant

License

CRNX

CRNX fundamentals

You can ask Aime